Study on the efficacy of sacubitril/valsartan in patients with heart failure with preserved ejection fraction undergoing peritoneal dialysis

Objective: Cardiovascular disease is the most common cause of death and morbidity in patients with end-stage renal disease. Sacubitril/valsartan (SAC/VAL) can reduce the risk of cardiovascular mortality among patients with heart failure (HF). The present study set out to evaluate the efficacy of SAC/VAL in the treatment of patients with heart failure with preserved ejection fraction (HFpEF) undergoing peritoneal dialysis (PD) (HFpEF & PD).Methods: A total of 160 patients with HFpEF & PD were enrolled and randomly divided into the control group (N= 80) and SAC/VAL group (N=80). The cardiac function efficacy, HF scoring efficacy, echocardiographic parameters, serological indicators, and 6-minute walking test were compared before and after treatment.Results: After 6 months of treatment, the total number of patients who responded to treatment in the SAC/VAL group was higher than that of the control group in terms of cardiac function and HF scoring efficacy. After treatment, levels of early diastolic/late diastolic filling velocity and left ventricular ejection fraction were increased in both groups, while the levels of left atrial diameter, 1eft ventricular end-diastolic diameter, 1eft ventricular end-systolic diameter, inter-ventricular septal diameter, and 1eft ventricular posterior wall diameter were decreased; the NT-proBNP levels were diminished in both groups, while hemoglobin levels and the 6-minute walk distance were increased; the systolic blood pressure, diastolic blood pressure, and 24-h ultrafiltration volume were lowered in all patients. The changes in these indexes in the SAC/VAL group were more obvious than those in the controls.Conclusion: SAC/VAL can significantly improve cardiac function in patients with HFpEF & PD.